Juvenile Arthritis

 

Majority of Patients With Juvenile Idiopathic Arthritis Achieved Clinical Remission

August 27, 2021

“Juvenile idiopathic arthritis constitutes a significant cause of disability and quality of life impairment in pediatric and adult patients,” investigators stated. “Recent advances in JIA treatment addressing more specific targets have led to better short and long-term disease outcomes."

Lower Anti-Vaccine Antibody Levels Observed in Patients With Juvenile Idiopathic Arthritis

July 28, 2021

Many children with juvenile idiopathic arthritis stop vaccinating when diagnosis is established, despite them being at a greater risk of infections than healthy children due to their aberrant immunity and the use of immunosuppressive drugs.

First-Line Biologics Reduce Glucocorticoid Exposure in Patients With Systemic Juvenile Idiopathic Arthritis

July 19, 2021

Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.

Safety and Efficacy of Secukinumab for Juvenile Idiopathic Arthritis

June 21, 2021

Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.

Daniel J. Lovell, MD, MPH: Juvenile Idiopathic Arthritis

April 05, 2021

This week, Rheumatology Network sat down with Daniel J. Lovell, MD, MPH, to discuss his study, “Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.”

Children Face Added Risks With Corticosteroid Use

October 22, 2020

Children who take oral corticosteroids for autoimmune conditions, such as juvenile arthritis, psoriasis, inflammatory bowel disease or other conditions, like asthma, have an increased risk of diabetes, high blood pressure, and blood clots, say researchers writing in the American Journal of Epidemiology.